Progressive multifocal leukoencephalopathy in patients treated with rituximab: a 20-year review from the Southern Network on Adverse Reactions
- 1 August 2021
- journal article
- review article
- Published by Elsevier in The Lancet Haematology
- Vol. 8 (8) , e593-e604
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute (1R01 CA125077–01A1)
This publication has 63 references indexed in Scilit:
- Inclusion of Rituximab in Treatment Protocols for Non-Hodgkin's Lymphomas and Risk for Progressive Multifocal LeukoencephalopathyThe Oncologist, 2010
- Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports projectBlood, 2009
- PML-IRIS in patients with HIV infectionNeurology, 2009
- Detection of JC Virus DNA and Proteins in the Bone Marrow of HIV‐Positive and HIV‐Negative Patients: Implications for Viral Latency and Neurotropic TransformationThe Journal of Infectious Diseases, 2009
- The role of polyomaviruses in human diseaseVirology, 2009
- Detection of JC virus DNA fragments but not proteins in normal brain tissueAnnals of Neurology, 2008
- Therapeutic B cell depletion impairs adaptive and autoreactive CD4+T cell activation in miceProceedings of the National Academy of Sciences, 2007
- Polyomavirus JC infects human brain microvascular endothelial cells independent of serotonin receptor 2AVirology, 2007
- Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patientsJournal of Neuroimmunology, 2006
- Involvement of JC Virus–Infected Mononuclear Cells from the Bone Marrow and Spleen in the Pathogenesis of Progressive Multifocal LeukoencephalopathyNew England Journal of Medicine, 1988